Oral Radiation Nuclear Decorporation Agents

口服辐射核修饰剂

• 批准号: 8159569
• 负责人: Michael Jay
• 金额: $ 663.24万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-30 至 2013-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8159569
• 关键词: Advanced Development; Calcium; Chelating Agents; Complex; Contracts; Excision; Gastrointestinal tract structure; Investigational New Drug Application; Metabolic Clearance Rate; National Institute of Allergy and Infectious Disease; Nebulizer; Nuclear; Oral; Pentetic Acid; Plasma; Plutonium; Prodrugs; Radiation; Radioactive; Radioisotopes; Research Personnel; Staging; Zinc; diethylenetriaminepentaacetate

The removal of certain internal radioactive contaminants can be accomplished by administering chelating agents that can preferentially complex with radionuclides in the body and increase their rate of clearance, thereby decreasing radiation exposure. Pentetate (diethylenetriaminepentaacetate) calcium trisodium (Ca-DTPA) and pentetate (diethylenetriaminepentaacetate) zinc trisodium (Zn-DTPA) have been shown to be effective in treating internal contamination with radionuclides such as plutonium, americium, or curium. However, because DTPA must be given intravenously or by nebulizer, it is not useful in a mass casualty situation. This Contract advances the development of an oral form of DTPA that is more suitable for a mass casualty situation.

可以通过施用可以优先与体内放射性核素复杂的螯合剂来完成某些内部放射性污染物并增加其清除率，从而降低辐射暴露。五酯（二乙基苯甲酸苯甲酸）钙（CA-DTPA）和五苯甲酸酯（二乙基苯甲酸苯甲酸苯甲酸苯甲酸苯甲酸苯胺丙氨酸）锌（Zn-DTPA）已被证明在对plutuim或cur的内部污染中有效治疗内部污染物，或者有效。但是，由于必须静脉注射或通过雾化器给予DTPA，因此在大规模的伤亡情况下它没有用。该合同推进了DTPA的口服形式的发展，该形式更适合大规模伤亡情况。